Resmed, Inc. (RMD) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Needham & Company Upgrades ResMed (RMD) to Buy
January 23, 2015 6:25 AM ESTNeedham & Company upgraded ResMed (NYSE: RMD) from Hold to Buy with a price target of $77.00 following solid Q3 results as the product cycle drove faster growth.
Analyst Mike Matson comments, "RMD's F2Q15 revenue and EPS beat consensus. RMD's new products drove faster... More
